Free tool
FAERS Monitor: Sodium Phosphates In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018892 or its brand name (Sodium Phosphates In Plastic Container, Sodium Phosphate, Dibasic, Heptahydrate, Sodium Phosphate, Monobasic, Monohydrate). Reports on generic versions are filed under their own applications.
Reports
214
Serious
197
92% of reports
Hospitalization
122
Death reported
51
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthenia19
- diarrhoea19
- renal failure acute19
- nausea18
- constipation16
- dehydration14
- fall14
- pyrexia14
- vomiting14
- dizziness13
- dyspnoea13
- urinary tract infection13
- pneumonia12
- fatigue11
- nephropathy11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 22 |
| 2007 | 19 |
| 2008 | 21 |
| 2009 | 28 |
| 2010 | 23 |
| 2011 | 14 |
| 2012 | 16 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 10 |
| 2023 | 5 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,945 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nephropathySignal | 11 | 115.9 | 65.2 | 1,140 |
| renal failure acuteSignal | 19 | 44.0 | 28.7 | 758 |
| dehydrationSignal | 14 | 10.3 | 6.2 | 109 |
| urinary tract infectionSignal | 13 | 7.5 | 4.4 | 67 |
| constipationSignal | 16 | 7.2 | 4.5 | 80 |
| astheniaSignal | 19 | 5.0 | 3.2 | 57 |
| fallSignal | 14 | 4.1 | 2.5 | 31 |
| pyrexiaSignal | 14 | 4.0 | 2.4 | 29 |
| pneumoniaSignal | 12 | 3.6 | 2.1 | 21 |
| vomitingSignal | 14 | 2.9 | 1.8 | 16 |
| diarrhoeaSignal | 19 | 2.9 | 1.9 | 22 |
| dizzinessSignal | 13 | 2.6 | 1.5 | 11 |
| dyspnoeaSignal | 13 | 2.3 | 1.3 | 8 |
| nauseaSignal | 18 | 2.2 | 1.4 | 12 |
| fatigue | 11 | 1.4 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.